Drug Profile
Research programme: carbohydrate-based vaccines - Ancora
Latest Information Update: 30 Nov 2013
Price :
$50
*
At a glance
- Originator Ancora Pharmaceuticals
- Class Carbohydrates; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malaria; Staphylococcal infections
Most Recent Events
- 07 Dec 2010 Ancora Pharmaceuticals receives federal grant from US Government under the Qualifying Therapeutic Discovery Program for vaccine development in Malaria (prevention)
- 07 Dec 2010 Preclinical trials in Staphylococcal infections (Prevention) in USA (unspecified route)
- 27 Oct 2005 Ancora Pharmaceuticals receives SBIR grant from the National Institutes of Health for development of malaria vaccines